156 related articles for article (PubMed ID: 22143549)
1. Studies on log Po/w of quinoxaline di-N-oxides: a comparison of RP-HPLC experimental and predictive approaches.
Moreno E; Gabano E; Torres E; Platts JA; Ravera M; Aldana I; Monge A; Pérez-Silanes S
Molecules; 2011 Sep; 16(9):7893-908. PubMed ID: 22143549
[TBL] [Abstract][Full Text] [Related]
2. New quinoxaline 1,4-di-N-oxides for treatment of tuberculosis.
Sainz Y; Montoya ME; Martínez-Crespo FJ; Ortega MA; López de Ceráin A; Monge A
Arzneimittelforschung; 1999 Jan; 49(1):55-9. PubMed ID: 10028381
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, 3D-QSAR analysis and biological evaluation of quinoxaline 1,4-di-N-oxide derivatives as antituberculosis agents.
Pan Y; Li P; Xie S; Tao Y; Chen D; Dai M; Hao H; Huang L; Wang Y; Wang L; Liu Z; Yuan Z
Bioorg Med Chem Lett; 2016 Aug; 26(16):4146-53. PubMed ID: 27426298
[TBL] [Abstract][Full Text] [Related]
4. Ester of Quinoxaline-7-carboxylate 1,4-di-N-oxide as Apoptosis Inductors in K-562 Cell Line: An in vitro, QSAR and DFT Study.
Rivera G; Andrade-Ochoa S; Romero MSO; Palos I; Monge A; Sanchez-Torres LE
Anticancer Agents Med Chem; 2017; 17(5):682-691. PubMed ID: 27396382
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents.
Jaso A; Zarranz B; Aldana I; Monge A
J Med Chem; 2005 Mar; 48(6):2019-25. PubMed ID: 15771444
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.
Santivañez-Veliz M; Pérez-Silanes S; Torres E; Moreno-Viguri E
Bioorg Med Chem Lett; 2016 May; 26(9):2188-93. PubMed ID: 27025343
[TBL] [Abstract][Full Text] [Related]
7. QSAR analysis for quinoxaline-2-carboxylate 1,4-di-N-oxides as anti-mycobacterial agents.
Vicente E; Duchowicz PR; Castro EA; Monge A
J Mol Graph Model; 2009 Aug; 28(1):28-36. PubMed ID: 19394254
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives.
Moreno E; Ancizu S; Pérez-Silanes S; Torres E; Aldana I; Monge A
Eur J Med Chem; 2010 Oct; 45(10):4418-26. PubMed ID: 20656380
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.
Vicente E; Villar R; Burguete A; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
Antimicrob Agents Chemother; 2008 Sep; 52(9):3321-6. PubMed ID: 18625764
[TBL] [Abstract][Full Text] [Related]
10. Anti-
Palos I; Luna-Herrera J; Lara-Ramírez EE; Loera-Piedra A; Fernández-Ramírez E; Aguilera-Arreola MG; Paz-González AD; Monge A; Wan B; Franzblau S; Rivera G
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914062
[TBL] [Abstract][Full Text] [Related]
11. Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide.
Ortega MA; Sainz Y; Montoya ME; Jaso A; Zarranz B; Aldana I; Monge A
Arzneimittelforschung; 2002; 52(2):113-9. PubMed ID: 11878199
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide against Entamoeba histolytica.
Duque-Montaño BE; Gómez-Caro LC; Sanchez-Sanchez M; Monge A; Hernández-Baltazar E; Rivera G; Torres-Angeles O
Bioorg Med Chem; 2013 Aug; 21(15):4550-8. PubMed ID: 23787289
[TBL] [Abstract][Full Text] [Related]
13. Beta-lactam antibiotics with N-oxide side chains. 1. Quinoxaline N-oxides.
Edwards ML; Bambury RE; Ritter HW
J Med Chem; 1976 Feb; 19(2):330-3. PubMed ID: 814237
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antiplasmodial activity of 3-furyl and 3-thienylquinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives.
Vicente E; Charnaud S; Bongard E; Villar R; Burguete A; Solano B; Ancizu S; Pérez-Silanes S; Aldana I; Vivas L; Monge A
Molecules; 2008 Jan; 13(1):69-77. PubMed ID: 18259130
[TBL] [Abstract][Full Text] [Related]
15. New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents.
Ancizu S; Moreno E; Solano B; Villar R; Burguete A; Torres E; Pérez-Silanes S; Aldana I; Monge A
Bioorg Med Chem; 2010 Apr; 18(7):2713-9. PubMed ID: 20233660
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, in vitro antitubercular activity and 3D-QSAR of novel quinoxaline derivatives.
Puratchikody A; Natarajan R; Jayapal M; Doble M
Chem Biol Drug Des; 2011 Dec; 78(6):988-98. PubMed ID: 21951363
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives.
Zarranz B; Jaso A; Aldana I; Monge A
Bioorg Med Chem; 2003 May; 11(10):2149-56. PubMed ID: 12713824
[TBL] [Abstract][Full Text] [Related]
18. In silico studies of quinoxaline-2-carboxamide 1,4-di-n-oxide derivatives as antimycobacterial agents.
Radwan AA; Abdel-Mageed WM
Molecules; 2014 Feb; 19(2):2247-60. PubMed ID: 24566302
[TBL] [Abstract][Full Text] [Related]
19. New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents.
Torres E; Moreno E; Ancizu S; Barea C; Galiano S; Aldana I; Monge A; Pérez-Silanes S
Bioorg Med Chem Lett; 2011 Jun; 21(12):3699-703. PubMed ID: 21570839
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues.
Solano B; Junnotula V; Marín A; Villar R; Burguete A; Vicente E; Pérez-Silanes S; Aldana I; Monge A; Dutta S; Sarkar U; Gates KS
J Med Chem; 2007 Nov; 50(22):5485-92. PubMed ID: 17910426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
